Trial Search Results

Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms

The primary objective of this study is to evaluate the long-term safety and tolerability of orally administered telotristat etiprate.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Lexicon Pharmaceuticals

Stanford Investigator(s):


  • Drug: Telotristat etiprate tablets (250 mg)


Phase 3


Inclusion Criteria:

   - Ongoing participation in a Phase 2 (LX1606.1-202-CS, LX1606.1-203-CS) or Phase 3
   (LX1606.1-301-CS, LX1606.1-303-CS) study

   - Patients of childbearing potential must agree to use an adequate method of
   contraception (defined as having a failure rate of <1% per year) during the study and
   for 12 weeks after the Follow-up visit.

   - Ability and willingness to provide written informed consent

Exclusion Criteria:

   - Major protocol violations or tolerability concerns in a Phase 2 (eg, LX1606.1-202-CS,
   LX1606.1-203-CS) or Phase 3 (eg, LX1606.1-301-CS, LX1606.1-303-CS) study

   - Positive pregnancy test

   - Presence of any clinically significant findings at entry for medical history,
   laboratory values, or physical examination

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting